 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Crescendo Aims for 'Full Launch Velocity' for Vectra DA, Focus on Educating RA Patients in 2013
January 09, 2013
Crescendo Aims for 'Full Launch Velocity' for Vectra DA, Focus on Educating RA Patients in 2013
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Studies Suggest Crescendo's Vectra DA Can Track Rheumatoid Arthritis in Variety of Settings
December 12, 2012 / Pharmacogenomics Reporter - Data Suggests Crescendo Test Tracks Rheumatoid Arthritis Patients' Response to Anti-TNF Therapies
November 9, 2011 / Pharmacogenomics Reporter - Crescendo Launches First Dx in Test Suite to Improve Care of Rheumatoid Arthritis Patients
November 17, 2010 / Pharmacogenomics Reporter - New York Clears Crescendo Bio to Offer RA Test
April 18, 2013 / GenomeWeb Daily News - Crescendo Bioscience Raises $28M in Series D Financing Round
January 3, 2013 / GenomeWeb Daily News